TR1801‐ADC: a highly potent cMet antibody–drug conjugate with high activity in patient‐derived xenograft models of solid tumors

cMet is a well‐characterized oncogene that is the target of many drugs including small molecule and biologic pathway inhibitors, and, more recently, antibody–drug conjugates (ADCs). However, the clinical benefit from cMet‐targeted therapy has been limited. We developed a novel cMet‐targeted ‘third‐g...

Descripción completa

Detalles Bibliográficos
Autores principales: Gymnopoulos, Marco, Betancourt, Oscar, Blot, Vincent, Fujita, Ryo, Galvan, Diana, Lieuw, Vincent, Nguyen, Sophie, Snedden, Jeanette, Stewart, Christine, Villicana, Jose, Wojciak, Jon, Wong, Eley, Pardo, Raul, Patel, Neki, D’Hooge, Francois, Vijayakrishnan, Balakumar, Barry, Conor, Hartley, John A., Howard, Philip W., Newman, Roland, Coronella, Julia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6944112/
https://www.ncbi.nlm.nih.gov/pubmed/31736230
http://dx.doi.org/10.1002/1878-0261.12600

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6944112/
https://www.ncbi.nlm.nih.gov/pubmed/31736230
http://dx.doi.org/10.1002/1878-0261.12600

Ejemplares similares